Inhibiting proteolytic enzymes (Proteases) is one means of counteracting viral infections, including SARS2 CoV2 invasion and the COVID-19 pandemic. Among others, the drug Paxlovid, just approved in the U.S., is based on this medical technology, which is also used in HIV treatment. On Jan. 20, 2022 (5 p.m.), the international online symposium "Proteases in SARS-CoV2 Infections" will address the latest findings in protease research and the development of corresponding agents against SARS-CoV2. The symposium is organized digitally via ZOOM by the Research Training Group 2606 "Protpath: Structured Doctoral Training in Proteolysis" of the University of Freiburg together with the International Proteolysis Society (IPS). Members of the press are also cordially invited. Co-chairs of the symposium are IPS Vice President Dr. Ruth Geiss-Friedlander from the University of Freiburg and IPS President Dr. Anthony O'Donoghue from the University of California.
Presenters are: Prof. Dr. Rolf Hilgenfeld (University of Lübeck), Prof. Dr. Joanne Lemieux (University of Alberta), Wioletta Rut (Wrocław University of Technology), Isabel Pablos (University of British Columbia), James Janetka (Washington University) and Georg Jocher (German Center for Neurodegenerative Diseases in Munich).
Registration is open until January 14, 2022 on the Research Training Group homepage. The login data for ZOOM will be sent to registered users via mail. More information about the IPS: https://www.protease.org/
Contact:
Dr. Ruth Geiss-Friedlander
Institute for Molecular Medicine and Cell Research
University of Freiburg
Tel.: 0761/203-9615
E-mail: ruth.geiss-friedlander@mol-med.uni-freiburg.de
Bastian Strauch
Office of University and Science Communications
University of Freiburg
Tel.: 0761/203-4301
E-mail: bastian.strauch@pr.uni-freiburg.de